Modulating immune responses
In principle, present AIT is based on two different approaches. One approach is to modulate TH2-based allergy towards a TH1 (inflammatory)-based immune response to block allergy-related IgE with allergen-specific IgG1 antibodies. While this approach provides relief to allergic patients, it is not directed towards the induction of lasting tolerance.
The other approach aims to induce tolerance by a administration of allergens or allergen-derived peptides for an extended period of time up to several years. While this approach has the potential of restoring immunological tolerance, the therapeutic efficiency is limited. Supporting tolerance-promoting strategies are required to boost the therapeutic efficacy of the approach.
The novel approach of Tolerogenics is based on a patent-protected technology, capable of inducing allergen-specific tolerance in peripheral dendritic cells (DCs) with high efficacy, which in turn, enhances the Treg population so it can regain control of the immune system.
The novel approach of Tolerogenics is unique in that it combines high therapeutic efficacy with safety and short treatment periods which will improve compliance of patients significantly.